Apatinib for treatment of HGF in advanced lung adenocarcinoma harboring EGFR activating mutation: a case report and review of literature

被引：0
作者：
Zhang, Jie [1 ]
Gu, Ting-Ting [1 ]
Li, Xiao-Xiao [1 ]
Wang, Cai-Hua [2 ]
Zeng, Da-Xiong [1 ]
Wang, Chang-Guo [1 ]
Huang, Jian-An [1 ]
Jiang, Jun-Hong [1 ]
机构：
[1] Soochow Univ, Dept Resp Med, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Nanjing Med Univ, Dept Crit Care Med, Affiliated Jiangning Hosp, Nanjing, Jiangsu, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2019年 / 12卷 / 01期
关键词：
Apatinib; HGF; primary resistance; lung adenocarcinoma; L858R; HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; GEFITINIB RESISTANCE; PHASE-II; CANCER; INHIBITOR; ANTIBODY; TKIS;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Hepatocyte growth factor (HGF) is a complex, multi-domain protein related to the blood proteinase precursor plasminogen, known to be detected in 29% of tumors with intrinsic resistance in EGFR mutant lung cancer. However, the proportion of HGF in primary resistance of lung adenocarcinoma is not clear. We describe the case of a 54-year-old non-smoking man who was diagnosed lung adenocarcinoma via pathology test. The lymph nodes of his right neck, submandibular, left axillary, and mediastinal were metastasized. Next generation sequencing of the patient showed L858R in 21 exon and overexpression of HGF. Apatinib is a salvage treatment for patients after failure in response to chemotherapy and icotinib. Therefore, apatinib might be an optional choice for advanced lung adenocarinoma patients with HGF overexpression as a post second-line treatment.
引用
收藏
页码：1094 / 1100
页数：7
相关论文
共 27 条
  • [1] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Bell, DW
    Gore, I
    Okimoto, RA
    Godin-Heymann, N
    Sordella, R
    Mulloy, R
    Sharma, SV
    Brannigan, BW
    Mohapatra, G
    Settleman, J
    Haber, DA
    [J]. NATURE GENETICS, 2005, 37 (12) : 1315 - 1316
  • [2] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [3] Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans
    Ding, Juefang
    Chen, Xiaoyan
    Gao, Zhiwei
    Dai, Xiaojian
    Li, Liang
    Xie, Cen
    Jiang, Haoyuan
    Zhang, Lijia
    Zhong, Dafang
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (06) : 1195 - 1210
  • [4] The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer Case Report and Review of Literature
    Ding, Lin
    Li, Qing-Jian
    You, Kai-Yun
    Jiang, Zhi-Min
    Yao, He-Rui
    [J]. MEDICINE, 2016, 95 (20)
  • [5] NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Akerley, Wallace
    Bazhenova, Lyudmila A.
    Borghaei, Hossein
    Camidge, David Ross
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dobelbower, M. Chris
    Govindan, Ramaswamy
    Hennon, Mark
    Horn, Leora
    Jahan, Thierry M.
    Komaki, Ritsuko
    Lackner, Rudy P.
    Lanuti, Michael
    Lilenbaum, Rogerio
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Sharma, Neelesh
    Stevenson, James
    Swanson, Scott J.
    Tauer, Kurt
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03): : 255 - 264
  • [6] Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
    Fang, Shen-Cun
    Zhang, Hai-Tao
    Zhang, Ying-Ming
    Xie, Wei-Ping
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 447 - 452
  • [7] Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Hicklin, DJ
    Ellis, LM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 1011 - 1027
  • [8] Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
    Hu, Xichun
    Zhang, Jian
    Xu, Binghe
    Jiang, Zefei
    Ragaz, Joseph
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Xiaojia
    Feng, Jifeng
    Pang, Danmei
    Fan, Minhao
    Li, Jin
    Wang, Biyun
    Wang, Zhonghua
    Zhang, Qunling
    Sun, Si
    Liao, Chunmei
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1961 - 1969
  • [9] ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma
    Jaenne, Pasi A.
    Meyerson, Matthew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 878 - 879
  • [10] Jiang Tao, 2015, Zhongguo Fei Ai Za Zhi, V18, P240, DOI 10.3779/j.issn.1009-3419.2015.04.09
123